Abstract
Dear editor There is increasing interest in the complex links between the immune system and cancer risk. Early data indicated decreased breast cancer risk for women with human immunodeficiency virus (HIV) infection compared to the general population [1]. A case-control study further showed that lower breast cancer risk in women with
Highlights
There is increasing interest in the complex links between the immune system and cancer risk
A case-control study further showed that lower breast cancer risk in women with human immunodeficiency virus (HIV) was significantly and independently linked to infection with HIV strains that bind to CXC chemokine receptor type 4 (CXCR-4) [2]
Given the data suggesting that the decreased risk of breast cancer in women with HIV infection is mediated by interactions with CXCR4, we hypothesized that the sera of women with Systemic lupus erythematosus (SLE) actively binds to CXCR4 antigen, which might invoke a pathway through which the lower breast cancer risk in SLE is mediated
Summary
There is increasing interest in the complex links between the immune system and cancer risk. Data indicated decreased breast cancer risk for women with human immunodeficiency virus (HIV) infection compared to the general population [1]. A case-control study further showed that lower breast cancer risk in women with HIV was significantly and independently linked to infection with HIV strains that bind to CXC chemokine receptor type 4 (CXCR-4) [2]. The authors of the case-control study hypothesized that, in women with HIV, involution of the abnormal precancerous cells is mediated by binding of CXCR4. Given the data suggesting that the decreased risk of breast cancer in women with HIV infection is mediated by interactions with CXCR4, we hypothesized that the sera of women with SLE actively binds to CXCR4 antigen, which might invoke a pathway through which the lower breast cancer risk in SLE is mediated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
